The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma

NCT03394508 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Rhinitis
Asthma
Allergy

Interventions

DRUG: ALK Alutard birch or 5-grasses
DRUG: ALK diluent 0,3% human albumin

Sponsor

Karolinska Institutet